Pieris Pharmaceuticals, Inc.

  • Home
  • About
  • Pipeline
  • Investors
    • Overview
    • News & Events
    • Publications
    • Presentations
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, Inc. Palvella Therapeutics (Nasdaq: PVLA), is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. For more information about the Company and updates, please visit www.palvellatx.com or follow us on LinkedIn.

Continue
  • Governance

  • Overview
  • Board of Directors
  • Board Committees
  • Governance Documents

Audit Committee Charter

Download Audit Committee Charter

Compensation and Management Development Committee Charter

Download Compensation and Management Development Committee Charter

Nominating & Corporate Governance Committee Charter

Download Nominating & Corporate Governance Committee Charter

Science and Technology Committee Charter

Download Science and Technology Committee Charter

Code of Conduct and Ethics and Whistleblower Policy

Download Code of Conduct and Ethics and Whistleblower Policy

Insider Trading Policy

Download Insider Trading Policy
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2025 Pieris Pharmaceuticals, Inc. All Rights Reserved.
Imprint Privacy Policy Disclaimer Sitemap Contact Us Manage Cookie Preferences